S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
BREAKING: Tiny biotech successfully treats blindness (Ad)
MarketBeat Week in Review – 3/27 - 3/31
UN body mulls deep sea mining amid demand for minerals
BREAKING: Tiny biotech successfully treats blindness (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
BREAKING: Tiny biotech successfully treats blindness (Ad)
Canada approves largest telecom deal in country's history
Medicare, Social Security could fall short over next decade
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
BREAKING: Tiny biotech successfully treats blindness (Ad)
MarketBeat Week in Review – 3/27 - 3/31
UN body mulls deep sea mining amid demand for minerals
BREAKING: Tiny biotech successfully treats blindness (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
BREAKING: Tiny biotech successfully treats blindness (Ad)
Canada approves largest telecom deal in country's history
Medicare, Social Security could fall short over next decade
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
BREAKING: Tiny biotech successfully treats blindness (Ad)
MarketBeat Week in Review – 3/27 - 3/31
UN body mulls deep sea mining amid demand for minerals
BREAKING: Tiny biotech successfully treats blindness (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
BREAKING: Tiny biotech successfully treats blindness (Ad)
Canada approves largest telecom deal in country's history
Medicare, Social Security could fall short over next decade
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
BREAKING: Tiny biotech successfully treats blindness (Ad)
MarketBeat Week in Review – 3/27 - 3/31
UN body mulls deep sea mining amid demand for minerals
BREAKING: Tiny biotech successfully treats blindness (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
BREAKING: Tiny biotech successfully treats blindness (Ad)
Canada approves largest telecom deal in country's history
Medicare, Social Security could fall short over next decade
NASDAQ:YTEN

Yield10 Bioscience - YTEN Stock Forecast, Price & News

$2.76
+0.01 (+0.36%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.60
$2.80
50-Day Range
$2.31
$4.10
52-Week Range
$1.63
$6.12
Volume
10,446 shs
Average Volume
78,035 shs
Market Capitalization
$13.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Yield10 Bioscience MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
334.8% Upside
$12.00 Price Target
Short Interest
Healthy
2.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.64) to ($0.80) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

Consumer Staples Sector

93rd out of 136 stocks

Agricultural Production - Crops Industry

8th out of 11 stocks


YTEN stock logo

About Yield10 Bioscience (NASDAQ:YTEN) Stock

Yield10 Bioscience, Inc. is an agricultural bioscience company, which engages in the development of oilseed Camelina sativa as a platform crop for large scale production of low carbon sustainable seed products. The company was founded by Anthony J. Sinskey, Simon F. Williams, and Oliver P. Peoples in 1992 and is headquartered in Woburn, MA.

Receive YTEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yield10 Bioscience and its competitors with MarketBeat's FREE daily newsletter.

YTEN Stock News Headlines

The Market Crash Shield is A.I.
Are you using the best technology to dominate April markets? This A.I. has traders doubting their methods. Attend This Live (FREE) A.I. Market Training. pixel
Lake Street Reaffirms Their Buy Rating on Yield10 Bioscience (YTEN)
Q4 2022 Yield10 Bioscience Inc Earnings Call
The Market Crash Shield is A.I.
Are you using the best technology to dominate April markets? This A.I. has traders doubting their methods. Attend This Live (FREE) A.I. Market Training. pixel
Short Volatility Alert: Yield10 Bioscience
Lake Street Keeps Their Buy Rating on Yield10 Bioscience (YTEN)
See More Headlines
Receive YTEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yield10 Bioscience and its competitors with MarketBeat's FREE daily newsletter.

YTEN Company Calendar

Last Earnings
11/09/2021
Today
3/31/2023
Next Earnings (Estimated)
5/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Agricultural production - crops
Sub-Industry
N/A
Current Symbol
NASDAQ:YTEN
Employees
29
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+334.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-13,570,000.00
Net Margins
-3,014.67%
Pretax Margin
-2,980.00%

Debt

Sales & Book Value

Annual Sales
$450,000.00
Book Value
$0.89 per share

Miscellaneous

Free Float
4,805,000
Market Cap
$13.99 million
Optionable
Not Optionable
Beta
1.75

Social Links


Key Executives

  • Oliver P. Peoples
    President, Chief Executive Officer & Director
  • Charles B. HaaserCharles B. Haaser
    Chief Accounting Officer, Treasurer & VP-Finance
  • Kristi D. Snell
    Chief Science Officer & Vice President-Research
  • Nicholas Renegar
    Director-Business Analytics & Operations
  • Lynne H. Brum
    Secretary, VP-Planning & Communications













YTEN Stock - Frequently Asked Questions

Should I buy or sell Yield10 Bioscience stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Yield10 Bioscience in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" YTEN shares.
View YTEN analyst ratings
or view top-rated stocks.

What is Yield10 Bioscience's stock price forecast for 2023?

2 equities research analysts have issued 12 month price objectives for Yield10 Bioscience's stock. Their YTEN share price forecasts range from $12.00 to $12.00. On average, they expect the company's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 334.8% from the stock's current price.
View analysts price targets for YTEN
or view top-rated stocks among Wall Street analysts.

How have YTEN shares performed in 2023?

Yield10 Bioscience's stock was trading at $1.6695 at the start of the year. Since then, YTEN stock has increased by 65.3% and is now trading at $2.76.
View the best growth stocks for 2023 here
.

When is Yield10 Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our YTEN earnings forecast
.

How were Yield10 Bioscience's earnings last quarter?

Yield10 Bioscience, Inc. (NASDAQ:YTEN) posted its quarterly earnings data on Tuesday, November, 9th. The specialty chemicals company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.16. The specialty chemicals company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.22 million. Yield10 Bioscience had a negative net margin of 3,014.67% and a negative trailing twelve-month return on equity of 154.59%. During the same quarter in the previous year, the business posted ($0.87) EPS.

When did Yield10 Bioscience's stock split?

Shares of Yield10 Bioscience reverse split on Thursday, January 16th 2020. The 1-40 reverse split was announced on Wednesday, January 15th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 15th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Yield10 Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Yield10 Bioscience investors own include KushCo (KSHB), OPKO Health (OPK), T2 Biosystems (TTOO), FuelCell Energy (FCEL), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX), Rigel Pharmaceuticals (RIGL), Advanced Micro Devices (AMD).

What is Yield10 Bioscience's stock symbol?

Yield10 Bioscience trades on the NASDAQ under the ticker symbol "YTEN."

Who are Yield10 Bioscience's major shareholders?

Yield10 Bioscience's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Cannell & Co. (5.22%). Insiders that own company stock include Anthony J Sinskey, Charles B Haaser and Jack W Schuler.
View institutional ownership trends
.

How do I buy shares of Yield10 Bioscience?

Shares of YTEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Yield10 Bioscience's stock price today?

One share of YTEN stock can currently be purchased for approximately $2.76.

How much money does Yield10 Bioscience make?

Yield10 Bioscience (NASDAQ:YTEN) has a market capitalization of $13.99 million and generates $450,000.00 in revenue each year. The specialty chemicals company earns $-13,570,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis.

How can I contact Yield10 Bioscience?

Yield10 Bioscience's mailing address is 19 PRESIDENTIAL WAY, WOBURN MA, 01801. The official website for the company is www.yield10bio.com. The specialty chemicals company can be reached via phone at (617) 583-1700, via email at brets@coreir.com, or via fax at 617-583-1768.

This page (NASDAQ:YTEN) was last updated on 4/1/2023 by MarketBeat.com Staff